The human leukocyte antigen class III haplotype approach: New insight in alzheimer’s disease inflammation hypothesis

Current Alzheimer Research

Volumn 10, Issue 10, 2013, Pages 1047-1056

  Maggioli, Elisa ^a   Boiocchi, Chiara ^b   Zorzetto, Michele ^a   Sinforiani, Elena ^b   Cereda, Cristina ^b   Ricevuti, Giovanni ^a   Cuccia, Mariaclara ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Alzheimer s disease; HLA class III; Inflammation

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HLA ANTIGEN; IMMUNOGLOBULIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HUMAN; INFLAMMATION; ITALY; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALZHEIMER DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA ANTIGENS; HUMANS; INFLAMMATION; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904917377     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113106660169     Document Type: Article

References (52)

1. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1143-53 (2001).
2. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36 (2009).
3. Candore G, Balistreri CR, Grimaldi MP, Vasto S, Listì F, Chiappelli M, et al. Age-related inflammatory disease: role of genetics and gender in the pathophysiology of Alzheimer's Disease. Ann N Y Acad Sci 1089: 472-86 (2006).
4. Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2: 8 (2005).
5. Eikelenboom P, Veerhuis R, Familian A, Hoozemans JJ, van Gool WA Rozemuller AJ. Neuroinflammation in plaque and vascular beta-amyloid disorders: clinical and therapeutic implications. Neurodegener Dis 5: 190-193 (2008).
6. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 7: 612-8 (2001).
7. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 83: 470S-474S (2006).
8. Pascual M, Baliño P, Alfonso-Loeches S, Aragón CM, Guerri C. Impact of TLR4 on behavioral and cognitive dysfunctions associ ated with alcohol-induced neuroinflammatory damage. Brain Behav Immun 25 (1): S80-91 (2011).
9. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 21: 335-76 (2003).
10. Xu Y, Yan J, Zhou P, Li J, Gao H, Li J, et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 97: 1-13 (2012).
11. In t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345: 1515-21 (2001).
12. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28: 639-647 (2007).
13. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 230: 27-34 (2011).
14. Sánchez-Ferro A, Benito-León J, Mitchell AJ, Bermejo-Pareja F. A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. Neuropsychiatr Dis Treat 9: 55-63 (2013).
15. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 48: 626-632 (1997).
16. Caruso C, Franceschi C, Licastro F. Genetics of neurodegenerative disorders. N Engl J Med 349: 193-4 (2003).
17. Licastro F, Chiappelli M. Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech Ageing Dev 124: 539-48 (2003).
18. Seripa D, Matera MG, Dal Forno G, Gravina C, Masullo C, Daniele A, et al. Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 26: 455-64 (2005).
19. Cereda C, Boiocchi C, Bongioanni P, Cova E, Guareschi S, Metelli MR, et al. TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol 194: 123-31 (2008).
20. Yu YC, Yang Z, Blanchong CA, Miller W. The human and mouse MHC class III region: a parade of 21 genes at the centromeric segment. Immunol 21: 320-328 (2000).
21. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955 (2001).
22. Boiocchi C, Bozzini S, Buzzi MP, Schirinzi S, Zorzetto M,, Pelissero G, et al. Age of onset of myocardial infarction: is promoter polymorphism of the RAGE gene implicated? Rejuvenation Res 14: 67-73 (2011).
23. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 54: 97-104 (2006).
24. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272: 16498-16506 (1997).
25. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50: 1505-1511 (2001).
26. Hudson BI, Stickland MH, Grant PJ, Futers TS. Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes 50: 2646-2651 (2001).
27. Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D, Belvito C, et al.-374 T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clinica Chimica Acta 354: 111-116 (2005).
28. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56: 321-339 (1997).
29. Blasko I, Marx F, Steiner E. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 13: 63-68 (1999).
30. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's diseaserelated cognitive deficits in transgenic mice. Neuron 45: 675-688 (2005).
31. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs 23: 713-25 (2009).
32. Kim JY, Moon SM, Ryu HJ. Identification of regulatory polymorphisms in the TNF-TNF receptor superfamily. Immunogenetics 57: 297-303 (2005).
33. Kroeger KM, Carville KS, Abraham LJ. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 34: 391-399 (1997).
34. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94: 3195-3199 (1997).
35. Candore G, Lio D, Colonna-Romano G. Pathogenesis of autoimmune diseases associated with 81 ancestral haplotype: effect of multiple gene interactions. Autoimmunity Rev 1: 29-35 (2002).
36. Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, et al. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 20: 145-54 (2007).
37. McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a casecontrol study. Lancet 357: 436-9 (2001).
38. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 50: 1505-1511 (1998).
39. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC. Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to agematched controls. Am J Med Genet 105: 332-42 (2001).
40. Culpan D, MacGowan SH, Ford JM, Nicoll JA, Griffin WS, Dewar D, et al. Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. Neurosci Lett 350: 61-5 (2003).
41. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177: 557-60 (1993).
42. Tarkowski E, Liljeroth AM, Nilsson A, Ricksten A, Davidsson P, Minthon L, et al. TNF gene polymorphism and its relation to in tracerebral production of TNFalpha and TNFbeta in AD. Neurology 54: 2077-81 (2000).
43. Alvarez V, Mata IF, González P, Lahoz CH, Martínez C, Peña J, et al. Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet 114: 574-7 (2002).
44. Laws SM, Perneczky R, Wagenpfeil S, Müller U, Förstl H, Martins RN, et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 26: 29-35 (2005).
45. Lio D, Annoni G, Licastro F, Crivello A, Forte GI, Scola L, et al Tumor necrosis factor-alpha-308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev 127: 567-71 (2006).
46. Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL, et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol 63: 1165-9 (2006).
47. Gnjec A, D'Costa KJ, Laws SM, Hedley R, Balakrishnan K, Taddei K, et al. Association of alleles carried at TNFA-850 and BAT1-22 with Alzheimer's disease. J Neuroinflammation 20: 5-36 (2008).
48. Wang B, Zhou S, Yang Z, Xie YC, Wang J,, Zhang P, et al. Genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A and Saitohin Q7R polymorphisms with Alzheimer's disease. J Neurol Sci 270: 148-51 (2008).
49. Tedde A, Putignano AL, Nacmias B, Bagnoli S, Cellini E, Sorbi S. Lack of association between TNF-alpha polymorphisms and Alzheimer's disease in an Italian cohort. Neurosci Lett 446: 139-42 (2008).
50. Yang L, Lu R, Jiang L, Liu Z, Peng Y. Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population. Brain Res 1247: 178-81 (2009).
51. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Cammà C, et al. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 61: 60-8 (2009).
52. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 132: 195-203 (2009).